

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of
ARNOULD-REGUIGNE, et al.

Examiner: **KAPUST, Rachel B.**

Application No.: **10/072,900**

Art Unit: **1647**

Filed: **February 12, 2002**

Title: **NUCLEIC ACIDS OF THE HUMAN
ABCA12 GENE, VECTORS
CONTAINING SUCH NUCLEIC
ACIDS AND USES THEREOF**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as First
Class Mail in an envelope addressed to Mail Stop
Sequence, Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450, on

13 August 2004

Date of Deposit


Signature

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Mail Stop Sequence
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,



Joel B. German, Reg. No. 48,676
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3444
Telefax (908) 231-2626

Aventis Docket No. ST01002 US NP